This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Feb 2020

PCI Pharma Services announces Bellwyck acquisition

PCI Pharma Services has bought Toronto-based packaging and labelling specialist Bellwyck Pharma Services, adding four GMP-compliant facilities in the US, Germany and Canada to its global network, the CDMO announced Tuesday.

Bellwyck’s supply chain offering includes clinical trial packaging, labeling and logistics for Phase I-IV studies and commercial packaging.

“We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities,” said Salim Haffar, chief executive officer, PCI Pharma Services.

With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 people.

The Bellwyck acquisition marks PCI’s third acquisition outside of the US in three years.

Mentioned Companies
PCI Pharma Services
View company profile